Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by Educatedopinionon Oct 30, 2020 12:10pm
140 Views
Post# 31813344

The future is Aristotle , not Covid testing.

The future is Aristotle , not Covid testing.There has been so much emphasis on the 3rd quarter revenue generated by Covid testing that a lot of people have lost focus of the main objective of the company .
Covid testing has very conveniently generated cash flow for the company , and from the looks of it , it could very well turn out to be substantial cash in the near future .
Most of the revenue generated should go towards the launch of Aristotle , which by the way seems to be on schedule and that is great news.
Why is it great news ? Because until Aristotle launch is confirmed , the institutions will be on the sidelines as  Covid testing is not a viable long term business model , Cancer prevention is .
Which leads us the SP , it is being manipulated ? My guess is yes , it is being held down to allow institutions to buy the shares cheap once the go ahead is confirmed .
So to those who are holding shares and warrants , unless you have access to the latest public offering , do not sell anything , the future looks very bright.
Cheers to all
Bullboard Posts